TaiMed Biologics : The Company's 2021 consolidated financial statements have been approved by the Board of Directors

Close

Today's Information

Provided by: TaiMed Biologics Inc.
SEQ_NO	1	Date of announcement	2022/03/11	Time of announcement	16:45:28
Subject	The Company's 2021 consolidated financial statements have been approved by the Board of Directors
Date of events	2022/03/11	To which item it meets	paragraph 31
Statement	1.Date of the board of directors submitted or approved:2022/03/11 2.Date of the audit committee approved:2022/03/11 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2021/1/1~2021/12/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):413,442 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):83,955 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):(486,367) 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):(470,933) 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):(470,933) 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):(470,933) 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):(1.87) 11.Total assets end of the period (thousand NTD):4,610,730 12.Total liabilities end of the period (thousand NTD):1,669,226 13.Equity attributable to owners of parent end of the period (thousand NTD):2,941,504 14.Any other matters that need to be specified: The low operating profit for the current period was mainly due to the estimated shelf life of some SBL products in process that could not meet the minimum shelf life stipulated in the sales contract. Therefore, the inventory allowance loss of NT$74,758,000 was recored in 2021 as the item of "other operating cost".